P1091: Trends in length of stay and steroid use in patients admitted with Acute Severe Ulcerative Colitis: Impact of intensified or accelerated infliximab dosingECCO'25Year: 2025
Authors: Bartlett , R.(1);Mohamedrashed , M.(1);Yogakanthi , S.(1);Chew , M.(1);Nedumannil , L.(1);Pearce , R.(1);Lucas , S.(1);Chauhan , A.(1);Lewis , D.(1);Kashkooli , S.(1);Garg , M.(1)*;
(1)Northern Health, Gastroenterology, Melbourne, Australia;
P1092: Real-life durability and utilization of biologics in pediatric inflammatory bowel disease: results from Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP) IBD registry.ECCO'25Year: 2025
Authors: Lega, S.(1)*;Manuela, G.(1);D'Arcangelo , G.(2);Di Pasquale, V.(3);Scarallo, L.(4);Ancona, S.(5);Fedele, F.(6);Zuin, G.(7);Graziano, F.(8);Norsa, L.(9);Gatti, S.(10);Illiceto, M.T.(11);Felici, E.(12);Corpino, M.(13);Pavanello, P.(14);Cozzali, R.(15);Alvisi, P.(16);Belluca, S.(17);Banzato, C.(18);Penagini, F.(19);Marseglia, A.(20);Faraci, S.(21);Luini, C.(22);Strisciuglio, C.(23);Moretti, C.(24);Martinelli, M.(6);Arrigo, S.(5);Lionetti, P.(4);Romano, C.(3);Aloi, M.(2);Bramuzzo, M.(1);
(1)Institute for Maternal and Child Health- IRCCS Burlo Garofolo, Pediatrics, Trieste, Italy;(2)Pediatric Gastroenterology Unit- Sapienza University – Umberto I, Pediatrics, Rome, Italy;(3)Pediatric Gastroenterology and Cystic Fibrosis Unit- Department of Human Pathology in Adulthood and Childhood "G. Barresi"- University Hospital "G. Martino", Pediatrics, Messina, Italy;(4)Gastroenterology and Nutrition Unit- Meyer Children Hospital IRCCS, Pediatrics, Florence, Italy;(5)Pediatric Gastroenterology and Endoscopy Unit – IRCCS Istituto Giannina Gaslini, Pediatrics, Genova, Italy;(6)Department of Translational Medical Science- Section of Pediatrics- University of Naples "Federico II, Pediatrics, Naples, Italy;(7)Pediatrics Department- Fondazione IRCCS San Gerardo dei Tintori, Pediatrics, Monza, Italy;(8)Pediatric Unit- Villa Sofia- Cervello Hospital- Palermo- Italy, Pediatrics, Palermo, Italy;(9)Paediatric Hepatology Gastroenterology and Transplantation- ASST Papa Giovanni XXIII, Pediatrics, Bergamo, Italy;(10)Università Politecnica delle Marche, Pediatrics, Ancona, Italy;(11)Paediatric Gastroenterology and Endoscopy- Department of Pediatrics – Ospedale Civile “Spirito Santo”, Pediatrics, Pescara, Italy;(12)Pediatric and Pediatric Emergency Unit- Children Hospital- AO SS Antonio e Biagio e C. Arrigo, Pediatrics, Alessandria, Italy;(13)Pediatric and Rare Disease Clinic- Microcitemico Hospital, Pediatrics, Cagliari, Italy;(14)Gastroenterology Unit- Departement pf Pediatrics Regional Hospital, Pediatrics, Treviso, Italy;(15)Pediatric Division- Università degli Studi di Perugia, Pediatrics, Perugia, Italy;(16)Gastroenterology Unit- Maggiore Hospital, Pediatrics, Bologna, Italy;(17)Gastroenterologia Pediatrica- Ospedale Infantile Regina Margherita- Dipartimento di Scienze della Sanità Pubblica e Pediatriche- Università degli Studi di Torino, Pediatrics, Turin, Italy;(18)Pediatric Division- University Hospital of Verona, Pediatrics, Verona, Italy;(19)Vittore Buzzi Children's Hospital- University of Milan, Pediatrics, Milan, Italy;(20)Fondazione IRCCS Casa Sollievo della Sofferenza- Divisione di Pediatria, Pediatrics, San Giovanni Rotondo, Italy;(21)Digestive Diseases Unit- Bambino Gesù Children's Hospital, Pediatrics, Rome, Italy;(22)Hospital “F. Del Ponte”, Pediatrics, Varese, Italy;(23)Depart. Woman- Child and General and specialistic Surgery. University of Campania Vanvitelli, Pediatrics, Naples, Italy;(24)Division of pediatrics- ASST GOM Niguarda, Pediatrics, Milan, Italy; SIGENP IBD Study Group
P1093: Personalized Tasty&Healthy whole-food diet for maintaining remission in children and adults with Crohn’s disease: results from the MyTasty open-label trialECCO'25Year: 2025
Authors: Plotkin, L.(1,2)*;Aharoni Frutkoff, Y.(1);Shavit, Z.(1);Focht, G.(1);Buchuk, R.(1);Lev-Zion, R.(1);Ledder, O.(1);Assa, A.(1);Sigall Boneh, R.(3);Weiss, B.(4);Slae , M.(5);Dotan, I.(6);Kierkuś, J.(7);Broide, E.(8);Griffiths, A.(9);Naftali, T.(10);Aloi, M.(11);Yerushalmy-Feler, A.(12);Schwerd, T.(13);Reifen, R.(2);Turner, D.(1);
(1)Shaare Zedek Medical Center, The Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)The Hebrew University of Jerusalem, Institute of Biochemistry- Food Science and Nutrition Robert H. Smith Faculty of Agriculture- Food and Environment, Rehovot, Israel;(3)The E. Wolfson Medical Center- Pediatric Gastroenterology and Nutrition Unit, Pediatric Gastroenterology and Nutrition Unit, Holon, Israel;(4)Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel;(5)Hadassah Ein Kerem, The Pediatric Gastroenterology Center, Jerusalem, Israel;(6)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(7)Children’s Memorial Health Institute, Pediatric Gastroenterology Unit, Warsaw, Poland;(8)Assaf Harofeh Medical Center, Pediatric Gastroenterology Unit, Zerifin, Israel;(9)Hospital for Sick Children, Pediatric Gastroenterology, Toronto, Canada;(10)Meir Hospital, Gastroenterology, Kfar Saba, Israel;(11)Sapienza University of Rome, Dept. of Pediatric Gastroenterology, Rome, Italy;(12)Tel Aviv Sourasky Medical Center, Pediatric Gastroenterology, Tel Aviv, Israel;(13)LMU München, Dr von Hauner Children`s Hospital, Munich, Germany; T&H
P1094: Serum Chitinase 3-like-1 (CHI3L1) is correlated to fecal calprotectin levels in IBD patients during pregnancyECCO'25Year: 2025
Authors: Schweistein, H.(1)*;Rave, A.(2);Glusman Bendersky, A.(1);Ollech, J.E.(1);Ariella , B.G.S.(3);
(1)Rabin Medical center- affiliated with Tel Aviv University, Gastroenterology Division, Petah Tikva, Israel;(2)Clalit health services- affiliated with Tel aviv University, Department of Family Medicine, Sharon Shomron, Israel;(3)Shaare-Zedek Medical Center- affiliated with Hebrew University, IBD center- Digestive Diseases Institute, Jerusalem, Israel;
P1095: Switching from Ustekinumab to Risankizumab Improves Outcomes in Crohn’s Disease: A Single-Centre Real-World Data AnalysisECCO'25Year: 2025
Authors: Qazi, U.(1)*;Padley, J.(1);Colwill, M.(1,2);Mehta, S.(1);Donovan, F.(1);Francisco Alves, A.M.(1);Pollok, R.(1,2);Poullis, A.(1,2);Patel, K.(1);Honap, S.(1,3);
(1)St George's University Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)City St George's- University of London, Institute of Infection and Immunity, London, United Kingdom;(3)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;
1. Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. N Engl J Med. 2024 Jul 18;391(3):213–23
P1096: The predictive value of intestinal ultrasound for treatment response in Inflammatory Bowel Disease: a systematic review and pooled data analysisECCO'25Year: 2025
Authors: Vos, H.(1)*;Teichert, C.(2);de Voogd, F.(2);Pruijt, M.(2);D'Haens, G.(2);Benninga, M.(1);Koot, B.(1);Gecse, K.(2);
(1)Emma Children’s Hospital- Amsterdam UMC, Department of Pediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P1097: Phase 1/2 study to assess safety, tolerability, and efficacy of XmAb942 (anti-TL1A) in healthy participants and participants with ulcerative colitisECCO'25Year: 2025
Authors: Hung, K.(1)*;Aggarwal, S.(1);Gargosky, S.(2);Peterson, C.(3);Ramanujan, S.(4);Banfield , C.(5);Manukyan , Z.(6);Hassan-Zahraee, M.(1);Kanodia, J.(7);Woo, J.(7);Szymkowski, D.(8);Visonneau, S.(9);Burington, B.(10);Trout, C.(11);Leone, D.(11);Dahiyat, B.(12);Gujrathi, S.(5);Desjarlais, J.(13);
(1)Xencor- Inc., Clinical Development, Pasadena, United States;(2)Xencor- Inc.- through its subsidiary Gale- Inc., Clinical Operations, Pasadena, United States;(3)Xencor- Inc.- through its subsidiary Gale- Inc., Regulatory Affairs, Pasadena, United States;(4)Xencor- Inc.- through its subsidiary Gale- Inc., Translational Biology, Pasadena, United States;(5)Xencor- Inc.- through its subsidiary Gale- Inc., Clinical Development, Pasadena, United States;(6)Xencor- Inc., Biostatistics, Pasadena, United States;(7)Xencor- Inc., Translational Biology, Pasadena, United States;(8)Xencor- Inc., Preclinical Operations, Pasadena, United States;(9)Xencor- Inc., Clinical Operations, Pasadena, United States;(10)Xencor- Inc., Biometrics, Pasadena, United States;(11)Xencor- Inc., Corporate Strategy, Pasadena, United States;(12)Xencor- Inc., Chief Executive Officer, Pasadena, United States;(13)Xencor- Inc., Chief Scientific Officer, Pasadena, United States;
Clinical trials identification: NCT06619990
P1098: The Clinical Spectrum of Acute Severe Ulcerative Colitis in the Biologic EraECCO'25Year: 2025
Authors: SinghD.M., A.(1)*;Luthra, M.(1);Bhardwaj, A.(1);Mahajan, R.(1);Sharma, R.(1);Singh, D.(1);Jain, D.(1);Goyal, O.(1);Mehta, V.(1);Kaur, K.(2);Gupta, Y.(1);Midha, V.(3);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(3)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;
P1099: Simple magnetic resonance imaging markers are non-inferior measures of treatment response compared to complex disease activity scores in patients with active Crohn’s diseaseECCO'25Year: 2025
Authors: Nejatbakhsh, E.(1)*;Rafaelsen, S.R.(2,3);Brodersen, J.B.(1,2);Knudsen, T.(1,2);Kjeldsen, J.(4,5,6);Juel, M.A.(1);Jensen, M.D.(1,2);
(1)Esbjerg and Grindsted Hospital – University Hospital of Southern Denmark, Department of Internal Medicine- Section of Gastroenterology, Esbjerg, Denmark;(2)University of Southern Denmark, Department of Regional Health Research, Odense, Denmark;(3)Lillebaelt Hospital – University Hospital of Southern Denmark, Department of Radiology, Vejle, Denmark;(4)Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark;(5)Odense University Hospital, OPEN Odense Patient data Explorative Network, Odense, Denmark;(6)University of Southern Denmark, Research Unit of Medical Gastroenterology- Department of Clinical Research, Odense, Denmark;
P1100: Effectiveness of Risankizumab in Crohn’s Disease, our real-world experience: Clinical, Biochemical and Ultrasonographic responses. A single centre, observational, retrospective study.ECCO'25Year: 2025
Authors: Moralejo Lozano, Ó.(1)*;Jarrín Pesantes, V.C.(1);Abanades Tercero, M.(1);Ruano Pérez, L.(1);Salmoral Luque, R.(1);Muñoz Rosas, C.(1);Gómez Rodriguez, R.Á.(1);
(1)Hospital Universitario de Toledo, Gastroenterology and Hepatology Department, Toledo, Spain;
- D'Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. doi:10.1016/S0140-6736(22)00467-6.
- Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031-2046. doi:10.1016/S0140-6736(22)00466-4.
- Ilvemark JFKF, Hansen T, Goodsall TM, et al. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. J Crohns Colitis. 2022;16(4):554-580. doi:10.1093/ecco-jcc/jjab173.
- Barreiro-de Acosta M, Nieto García L, Poncela M, et al. OP043 Real-world short-term effectiveness of Risankizumab in refractory Crohn’s disease: RISANCROHN study from the ENEIDA registry. UEG Week 2024 Oral Presentations. United European Gastroenterol J. 2024;12(Suppl 8): 2050-6406. doi.org/10.1002/ueg2.12614.
P1101: Real-world effectiveness and safety of Risankizumab in Crohn’s DiseaseECCO'25Year: 2025
Authors: McShane, C.(1)*;Olivera Sendra, P.A.(1);Kim, J.(1);Milgrom, R.(1);Stempak, J.(1);Nguyen, G.(1);Weizman, A.V.(1);Croitoru, K.(1);Gallinger, Z.(1);Huang, V.(1);Steinhart, H.(1);Targownik, L.(1);Lee, S.H.(1);Silverberg, M.(1);
(1)Mount Sinai Hospital, The Zane Cohen Centre for Digestive Diseases, Toronto, Canada;
P1102: Albumin predicts post-operative complications in Acute Severe Ulcerative ColitisECCO'25Year: 2025
Authors: Hodges, P.(1)*;Phillips, J.(2);King, H.(3);Creamer, J.(4);Kitchin, A.(4);Carter, O.(5);Tyrrell-Price, J.(2);
(1)Somerset NHS Foundation Trust, Gastroenterology, Yeovil, United Kingdom;(2)University Hospitals Bristol and Weston NHS Foundation Trust, Gastroenterology, Bristol, United Kingdom;(3)Gloucestershire Hospitals NHS Foundation Trust, Gastroenterology, Gloucester, United Kingdom;(4)Somerset NHS Foundation Trust, Gastroenterology, Taunton, United Kingdom;(5)Royal United Hospitals Bath NHS Foundation Trust, Gastroenterology, Bath, United Kingdom; Severn and Peninsula Research in Gastroenterology Trainee Network (SPRinG)
1. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97(3):404-9.
P1103: Thromboembolic and cardiovascular risk profiles in ulcerative colitis patients initiating advanced therapies: a single-center studyECCO'25Year: 2025
Authors: Calvez, V.(1)*;Cuccia, G.(2);Del Gaudio, A.(2);Capobianco, I.(2);Parisio, L.(2);Gasbarrini, A.(2);Scaldaferri, F.(2);Carbone, L.(3);Pugliese, D.(2);
(1)Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli Dipartimento di scienze mediche e chirurgiche, Rome, Italy;(2)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Catholic University of Rome, Department of Translational Medicine and Surgery, Rome, Italy;(3)Ospedale Isola Tiberina Gemelli Isola- Rome Medicina d'Urgenza e Medicina Interna- Rome- Italy, Medicina d'Urgenza e Medicina Interna, Rome, Italy;
References
[1] Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel J-F. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. Journal of Crohn’s and Colitis 2014;8:469–79. https://doi.org/10.1016/j.crohns.2013.09.021.
[2] Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022;386:316–26. https://doi.org/10.1056/NEJMoa2109927.
[3] EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders | European Medicines Agency n.d. https://www.ema.europa.eu/en/news/ema-confirms-measures-minimise-risk-serious-side-effects- janus-kinase-inhibitors-chronic-inflammatory-disorders (accessed April 25, 2024).
[4] Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Sperling LS, Virani SS, et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology 2019;73:3153–67. https://doi.org/10.1016/j.jacc.2018.11.005.
P1104: Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinibECCO'25Year: 2025
Authors: SinghD.M., A.(1)*;Bhardwaj, A.(1);Jain, D.(1);Sharma, R.(1);Singh, D.(1);Mahajan, R.(1);Kaur, K.(2);Singh, A.(3);Narang, V.(3);Kaur, H.(3);Singh, M.(4);Gupta, P.(4);Sehgal, T.(4);Midha, V.(4);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Pharmacology, Ludhiana, India;(3)Dayanand Medical College and Hospital, Pathology, Ludhiana, India;(4)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;
P1105: Reswitching Anti-TNF’s as Third-Line Biologic Therapy After Second-Line Failures: Factors Influencing OutcomesECCO'25Year: 2025
Authors: Akpınar, A.(1)*;Gur, M.B.(2);Bakkaloglu, O.K.(3);Vatansever, H.(2);Eskazan, T.(1);Hatemi, A.I.(1);Erzin, Y.Z.(1);Celik, A.F.(1);
(1)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;(2)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey;(3)Kosuyolu High Specialization Education and Research Hospital, Gastroenterology, Istanbul, Turkey;
P1106: Early surgical treatment after diagnosis of anal lesions of CD may reduce risk of and colostomy and rectal amputation.ECCO'25Year: 2025
Authors: Sako, M.(1)*;Okamoto, K.(2);
(1)Tokyo Yamate Medical Center, Center for Inflammatory Bowel Disease, Shinjuku, Japan;(2)Tokyo Yamate Medical Center, Department of Colorectal surgery, Shinjuku, Japan;
P1107: Biosimilar but not quite the same?: Post-induction levels of infliximab differ between brandsECCO'25Year: 2025
Authors: Patel, P.(1)*;Love, M.(1);Rimmer, P.(1);Cooney, R.(1);Hazel, K.(1);
(1)University Hospitals Birmingham NHS Foundation Trust, Department of Gastroenterology- Queen Elizabeth Hospital, Birmingham, United Kingdom;
P1108: Endoscopic Sleeve Gastroplasty for management of Obesity in patient suffer from Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Carlino, G.(1)*;Pontecorvi, V.(1);Bartocci, B.(2);Matteo, M.V.(1);Gualtieri, L.(3);De Siena, M.(1);Lopetuso, L.R.(4);Laterza, L.(4);Bove, V.(1);Pugliese, D.(4);Scaldaferri, F.(4);Spada, C.(1);Gasbarrini, A.(4);Boškoski, I.(1);
(1)Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, Surgical Digestive Endoscopy, Rome, Italy;(2)Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, Gastroenterology and Surgical Digestive Endoscopy, Rome, Italy;(3)Sapienza University of Rome, Department of Surgery, Rome, Italy;(4)Università Cattolica del Sacro Cuore- Fondazione Policlinico Gemelli IRCCS, Medicina Interna e Gastroenterologia- CEMAD Centro Malattie dell'Apparato Digerente- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;
1.Johnson AM, Loftus EV. Impact of Obesity on the Management of Inflammatory Bowel Disease. Gastroenterology & Hepatology. 2020;16(7):350.
2.Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110-121. doi:10.1038/nrgastro.2016.181
3.Pugliese D, Schepis T, Bove V, Privitera G, Boskoski I, Armuzzi A. Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report. Inflammatory Bowel Diseases. 2021;27(4):e49-e50. doi:10.1093/ibd/izaa334
4.Johnson AM, Storm AC, Mahmoud T, et al. Endoscopic Bariatric Therapies for the Management of Obesity in Patients with Inflammatory Bowel Disease. OBES SURG. 2023;33(2):676-681. doi:10.1007/s11695-022-06376-3
P1109: Evaluation of patient-reported outcome measures (PROMs) of IBD patients who completed upadacitinib induction period.ECCO'25Year: 2025
Authors: KavProf., T.(1)*;Unal, N.(2);Bakkaloglu , O.K.(3);Kani, T.(4);Akpinar, A.(3);Akincioglu, P.(5);Eskazan, T.(3);Balamir, M.(3);Dagci, G.(6);Sendur, İ.N.(1);Buyuktorun, I.(7);Barutcu, S.(8);Bengi , G.(7);Cavus, B.(6);Oruc, N.(2);Atug, O.(4);Dincer, D.(5);Hatemi, A.I.(3);Erzin, Y.Z.(3);Tezel, A.(9);Toruner, M.(10);Celik, A.F.(3);Akyuz, F.(6);
(1)Hacettepe University Faculty of Medicine, Gastroenterology, Ankara, Turkey;(2)Ege University Faculty of Medicine, Gastroenterology, Izmir, Turkey;(3)Cerrahpasa University Faculty of medicine, Gastroenterology, Istanbul, Turkey;(4)Marmara University Faculty of Medicine, Gastroenterology, Istanbul, Turkey;(5)Akdeniz University Faculty of Medicine, Gastroenterology, Antalya, Turkey;(6)Istanbul University Faculty of Medicine, Gastroenterology, Istanbul, Turkey;(7)Dokuz Eylul University Faculty of Medicine, Gastroenterology, Izmir, Turkey;(8)Gaziantep University Faculty of Medicine, Gastroenterology, Gaziantep, Turkey;(9)Trakya University Faculty of Medicine, Gastroenterology, Edirne, Turkey;(10)Ankara University Faculty of Medicine, Gastroenterology, Ankara, Turkey;
P1110: Results from the UPITA-Colitis Registry on the Effectiveness and Safety of Upadacitinib in the Induction phase in Patients with Ulcerative Colitis.ECCO'25Year: 2025
Authors: Caballero Mateos, A.M.(1)*;González-Parra, A.C.(2);Gutiérrez-Holanda, C.(3);Trapero-Martínez, A.M.(4);Hernández-Martínez, Á.(5);Rojas-Feria, M.(6);Martín-Rodríguez, M.D.M.(7);Rodríguez-González, F.J.(8);Saldaña, L.(9);Benítez, J.M.(10);Gómez-Delgado, E.(11);Miras, L.(12);González, J.(13);Mata, F.J.(14);Olmedo-Martín, R.V.(15);
(1)Santa Ana Hospital, Gastroenterology, Motril- Granada, Spain;(2)Virgen Macarena University Hospital, Gastroenterology, Seville, Spain;(3)San Cecilio Universityl Hospital, Gastroenterology, Granada, Spain;(4)University Hospital, Gastroenterology, Jaén, Spain;(5)Torrecárdenas University Hospital, Gastroenterology, Almería, Spain;(6)Virgen del Rocío University Hospital, Gastroenterology, Seville, Spain;(7)Virgen de las Nieves Universityl Hospital, Gastroenterology, Granada, Spain;(8)Virgen de la Victoria Universit Hospital, Gastroenterology, Málaga, Spain;(9)Costa del Sol Hospital, Gastroenterology, Marbella, Spain;(10)Reina Sofía Universityl Hospital, Gastroenterology, Córdoba, Spain;(11)Juan Ramón Jiménez Hospital, Gastroenterology, Huelva, Spain;(12)El Poniente Hospital, Gastroenterology, El Ejido, Sri Lanka;(13)La Inmaculada Hospital, Gastroenterology, Huércal Overa, Spain;(14)Puerto Real Hospital, Gastroenterology, Puerto Real, Spain;(15)Regional Hospital, Gastroenterology, Málaga, Spain; GATEII
- Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26. Erratum in: Lancet. 2022 Sep 24;400(10357):996
- D’Haens G, Lindsay JO, Panaccione R, Schreiber S. Ulcerative colitis: shifting sands. Drugs R D 2019; 19: 227–34.9- Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am 2014; 43: 603–17